Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma
10.3343/alm.2021.41.3.259
- Author:
Min Young LEE
1
;
Chan-Jeoung PARK
;
Young-Uk CHO
;
Eunkyoung YOU
;
Seongsoo JANG
;
Eul Ju SEO
;
Jung-Hee LEE
;
Dok Hyun YOON
;
Cheolwon SUH
Author Information
1. Department of Laboratory Medicine, Kyung Hee University School of Medicine and Kyung Hee University Hospital, Gangdong, Seoul, Korea
- Publication Type:Original Article
- From:Annals of Laboratory Medicine
2021;41(3):259-267
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Plasma cell myeloma (PCM) is caused by immune dysregulation. We evaluated the expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets in PCM patients according to disease course and cytogenetic abnormalities.This study aimed to find a target group suitable for therapeutic use of PD-1 blockade in PCM.
Methods:A total of 188 bone marrow (BM) samples from 166 PCM patients and 32 controls were prospectively collected between May 2016 and May 2017. PD-1 expression on BM T cell subsets was measured using flow cytometry.
Results:At diagnosis, the median PD-1 expression on CD4+ T cells was 24.6%, which did not significantly differ from that in controls. After stem cell transplantation, PD-1 expression on CD4+ T cells was higher than that at diagnosis (P < 0.001), regardless of residual disease. PD-1 expression on CD4+ T cells in patients with residual disease after chemotherapy was significantly higher than that at diagnosis (P = 0.001) and after complete remission following chemotherapy (P = 0.044). PD-1 expression on CD8+ T cells was higher in PCM patients with cytogenetic abnormalities, including monosomy 13, 1q gain, complex karyotype, and hypodiploidy.
Conclusions:PD-1 blockade might have therapeutic potential in refractory PCM patients after chemotherapy, especially in those with high- or intermediate-risk cytogenetic abnormalities.
